Association between baseline characteristics and clinically relevant fatigue, pain, and decreased QOL
| Variable . | Fatigue ≥5, odds ratio (95% CI) . | P value . | Pain ≥5, odds ratio (95% CI) . | P value . | QOL ≤5, odds ratio (95% CI) . | P value . |
|---|---|---|---|---|---|---|
| Age | 1.03 (1.01-1.04) | <.001 | 1.01 (1.00-1.02) | .18 | 1.02 (1.00-1.03) | .02 |
| >65 y | 1.4 (1.0-1.8) | .04 | 1.0 (0.8-1.4) | .84 | 1.1 (0.8-1.4) | .51 |
| >75 y | 2.0 (1.4-2.9) | <.001 | 1.3 (0.9-1.8) | .19 | 1.6 (1.1-2.3) | .01 |
| Female | 1.4 (1.0-1.9) | .03 | 1.7 (1.2-2.3) | .001 | 1.0 (0.7-1.3) | .76 |
| CCI ≥3 | 1.4 (1.0-2.0) | .03 | 1.5 (1.1-2.1) | .02 | 1.1 (0.8-1.5) | .67 |
| ISS III (vs I/II) | 2.2 (1.5-3.2) | <.001 | 1.8 (1.3-2.6) | .002 | 1.6 (1.1-2.4) | .02 |
| High-risk FISH∗ | 1.0 (0.8-1.5) | .85 | 1.0 (0.7-1.5) | .99 | 0.9 (0.6-1.4) | .63 |
| R-ISS III | 2.8 (1.5-5.0) | <.001 | 2.3 (1.3-4.1) | .003 | 2.4 (1.4-4.3) | .003 |
| Hb <10 g/dL | 2.3 (1.7-3.3) | <.001 | 1.5 (1.1-2.2) | .02 | 1.7 (1.2-2.4) | .003 |
| Ca >11 mg/dL | 0.9 (0.4-2.0) | .88 | 1.4 (0.6-3.1) | .39 | 2.7 (1.3-5.8) | .01 |
| Cr >2 mg/dL | 1.7 (1.0-2.9) | .05 | 1.3 (0.7-2.3) | .36 | 0.8 (0.5-1.5) | .59 |
| BMPCs ≥60 (%) | 1.7 (1.2-2.3) | .001 | 1.7 (1.2-2.4) | .001 | 1.4 (1.0-1.9) | .06 |
| Lytic lesions | 1.5 (1.1-2.1) | .02 | 2.5 (1.7-3.6) | <.001 | 1.4 (1.0-2.1) | .05 |
| ASCT after induction | 0.7 (0.5-1.0) | .03 | 0.8 (0.6-1.1) | .20 | 0.7 (0.5-1.0) | .04 |
| Fatigue, ≥5 | NA | NA | ||||
| Pain, ≥5 | 9.3 (6.5-13.2) | <.001 | NA | NA | ||
| QOL, ≤5 | 3.8 (2.7-5.2) | <.001 | 4.6 (3.3-6.4) | <.001 | NA | NA |
| Variable . | Fatigue ≥5, odds ratio (95% CI) . | P value . | Pain ≥5, odds ratio (95% CI) . | P value . | QOL ≤5, odds ratio (95% CI) . | P value . |
|---|---|---|---|---|---|---|
| Age | 1.03 (1.01-1.04) | <.001 | 1.01 (1.00-1.02) | .18 | 1.02 (1.00-1.03) | .02 |
| >65 y | 1.4 (1.0-1.8) | .04 | 1.0 (0.8-1.4) | .84 | 1.1 (0.8-1.4) | .51 |
| >75 y | 2.0 (1.4-2.9) | <.001 | 1.3 (0.9-1.8) | .19 | 1.6 (1.1-2.3) | .01 |
| Female | 1.4 (1.0-1.9) | .03 | 1.7 (1.2-2.3) | .001 | 1.0 (0.7-1.3) | .76 |
| CCI ≥3 | 1.4 (1.0-2.0) | .03 | 1.5 (1.1-2.1) | .02 | 1.1 (0.8-1.5) | .67 |
| ISS III (vs I/II) | 2.2 (1.5-3.2) | <.001 | 1.8 (1.3-2.6) | .002 | 1.6 (1.1-2.4) | .02 |
| High-risk FISH∗ | 1.0 (0.8-1.5) | .85 | 1.0 (0.7-1.5) | .99 | 0.9 (0.6-1.4) | .63 |
| R-ISS III | 2.8 (1.5-5.0) | <.001 | 2.3 (1.3-4.1) | .003 | 2.4 (1.4-4.3) | .003 |
| Hb <10 g/dL | 2.3 (1.7-3.3) | <.001 | 1.5 (1.1-2.2) | .02 | 1.7 (1.2-2.4) | .003 |
| Ca >11 mg/dL | 0.9 (0.4-2.0) | .88 | 1.4 (0.6-3.1) | .39 | 2.7 (1.3-5.8) | .01 |
| Cr >2 mg/dL | 1.7 (1.0-2.9) | .05 | 1.3 (0.7-2.3) | .36 | 0.8 (0.5-1.5) | .59 |
| BMPCs ≥60 (%) | 1.7 (1.2-2.3) | .001 | 1.7 (1.2-2.4) | .001 | 1.4 (1.0-1.9) | .06 |
| Lytic lesions | 1.5 (1.1-2.1) | .02 | 2.5 (1.7-3.6) | <.001 | 1.4 (1.0-2.1) | .05 |
| ASCT after induction | 0.7 (0.5-1.0) | .03 | 0.8 (0.6-1.1) | .20 | 0.7 (0.5-1.0) | .04 |
| Fatigue, ≥5 | NA | NA | ||||
| Pain, ≥5 | 9.3 (6.5-13.2) | <.001 | NA | NA | ||
| QOL, ≤5 | 3.8 (2.7-5.2) | <.001 | 4.6 (3.3-6.4) | <.001 | NA | NA |
BMPC, bone marrow plasma cells; Ca, calcium; Cr, creatinine; Hb, hemoglobin; R-ISS, revised ISS.
Statistically significant P values are indicated in bold.
Defined as presence of t(4;14), t(14;16), t(16;20), del 17p, and/or 1q gain/amplification.